Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Clinical Research in Southampton
Southampton Children's Hospital
A
A
A
Text only
| Accessibility | Privacy and cookies
"Helpful, informative, polite and friendly staff put my mind at ease"
Patient feedback
Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us
You are here:
Home
>
Search results
Search
Browse site A to Z
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Search results
Go To Advanced Search
Search
You could also try:
continuously (64)
Pembrolizumab Ver 1 skin
Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf
Nivolumab Ver 1.1 skin
Description
Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanc
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf
MelanomaBleomycinECT
Description
ChemotherapApril 17y Protocol SKIN CANCER BLEOMYCIN (ELECTROCHEMOTHERAPY) Please note this protocol only refers to the administration of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/MelanomaBleomycinECT.pdf
Ipilimumab Ver 1
Description
Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authori
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf
Dabrafenib Ver 1
Description
Chemotherapy Protocol SKIN CANCER DABRAFENIB Regimen Skin – Dabrafenib Indication Dabrafenib is recommended as an option for the first li
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinDabrafenibVer1.pdf
Nivolumab_240mg
Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • T
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf
Nivolumab
Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or met
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf
Methotrexate ver 1
Description
Chemotherapy Protocol HEAD AND NECK CANCER METHOTREXATE Regimen Head and Neck Cancer – Methotrexate Indication Advanced head and neck can
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Methotrexate-ver-1.pdf
Cisplatin (100)-Radiotherapy
Description
Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN (100) RT Regimen Head and Neck Cancer – Cisplatin (100) RT Indication Radical trea
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Cisplatin100-Radiotherapy.pdf
Cisplatin (100) RT (21 day)
Description
Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN (100) RT (21 day) Regimen Head and Neck Cancer – Cisplatin (100) RT (21 day) Indic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Cisplatin-100-RT-21-day.pdf
321
to
330
of
733
Previous
…
31
32
33
34
35
…
Next
Site policies
Report a problem with this page
Privacy and cookies
Site map
Translation
Last updated: 14 September 2019
Contact details
University Hospital Southampton NHS Foundation Trust
Tremona Road
Southampton
Hampshire
SO16 6YD
Telephone: 023 8077 7222
Useful links
Home
Getting here
What to do in an emergency
Research
Working here
Education
© 2014 University Hospital Southampton NHS Foundation Trust
Browser does not support script.
Browser does not support script.